We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for olipudase alfa (Sanofi-Aventis Australia Pty Ltd)
Active ingredients
olipudase alfa
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Powder for injection
Indication
Treatment of Acid sphingomyelinase deficiency (ASMD)
Therapeutic area
Inherited metabolic disorders